In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Body-based burial: Students imagine urns made from blood and hair
In Slovenia, students at University of Ljubljana have used biobased materials for a variety of design projects, including a biodegradable urn made of blood...
Uttar Pradesh eyes cow poop plastics to boost rural economy
In Uttar Pradesh, a government project is collecting cow dung to convert into usable products such as bioplastics, textiles, and paper.
The Press Trust...
Luxury brand Velvet Eyewear lauds advances in biobased acetate
In California, luxury women’s eyewear brand Velvet Eyewear has unveiled its first biobased eyewear collection.
Crafted from renewable sources like wood pulp and cotton...